Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Description

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

Conditions

Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR

Talk to us

Study Overview

On this page

Study Details

Study overview

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Condition
Transthyretin Amyloidosis
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Research Site, Los Angeles, California, United States, 90095

San Francisco

Research Site, San Francisco, California, United States, 94025

San Francisco

Research Site, San Francisco, California, United States, 94143

Washington

Research Site, Washington, District of Columbia, United States, 20010

Indianapolis

Research Site, Indianapolis, Indiana, United States, 06200

Boston

Research Site, Boston, Massachusetts, United States, 02111

Saint Louis

Research Site, Saint Louis, Missouri, United States, 63110

New Brunswick

Research Site, New Brunswick, New Jersey, United States, 08901

Manhasset

Research Site, Manhasset, New York, United States, 11030

Germantown

Research Site, Germantown, Tennessee, United States, 38138

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patient willing and able to provide written informed consent to participate in the study
  • * Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis
  • * Aged ≥18 years at the time of signing the informed consent
  • * Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)
  • * Concurrent participation in any interventional trial for ATTR amyloidosis
  • * Involvement in the planning and/or conduct of the current study
  • * Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)
  • * Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers

Ages Eligible for Study

18 Years to 130 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

AstraZeneca,

Study Record Dates

2031-06-27